1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
627423ECC902326E085257450007210DB
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/merger-acquisition-integration-what-bio-pharma-companies-need-to-know
18
19
203.209.80.217
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25BMR




Products & Services

M&A Integration Excellence: What Bio-Pharma Companies Need to Know

ID: POP-224


Features:

25 Info Graphics

14 Data Graphics

221 Metrics

83 Narratives

29 Best Practices


Pages: 107


Published: Pre-2014


Delivery Format: Shipped


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
This benchmarking study was conducted to examine winning bio-pharmaceutical M&A integration strategies to provide field benchmarks, lessons learned insights and best practice observations regarding the strategic combination of biotechnology and pharmaceutical assets to optimize ROI.


Executives involved in the merger and acquisition integration process can use this research to ensure their integration strategy reflects the critical lessons learned that participants shared from scores of bio-pharma integrations.


Industries Profiled:
Medical Device; Pharmaceutical; Biotech; Health Care; Manufacturing


Companies Profiled:
3M Pharmaceuticals; Takeda Pharmaceuticals; Solvay Pharmaceuticals; SIRO Clinpharm; QLT Inc.; Pfizer; Nizhpharm; Merial; Medtrina; Lilly; Kimble Chase; Johnson & Johnson Healthcare Systems; Indoco; Incite World; Heel; Eisai; Covidien; Coloplast; Baxter Healthcare; ATG; Alexza Pharmaceuticals; Allergan; Absolute Science; Abbott Laboratories

Study Snapshot

The data for this benchmarking study was collected utilizing an online survey instrument and several deep-dive executive interviews. Bio-pharma integration leaders and senior staff from 26 pharmaceutical and biotechnology companies participated in this research.

Key topics include:

  • Structure for Integration
  • Pre-Integration Planning Activities
  • Integration Risk Management
  • Integration Functional Excellence
  • Communications Excellence
  • Understanding & Managing Cultural Issues
  • Post-Deal Closure Integration Activities
  • Trends in M&A Integration
  • Integration Lessons Learned

Sample Key Findings

Integration structure should reflect the acquired assets & business objectives
  • Communications excellence is a foundation for succesful integration
  • Understanding and managing cultural issues is vital to assessing and executing successful integration


Sample List of Charts & Exhibits

Industry Integration Functional Efficacy
  • Efficacy of Integration Structural Approaches
  • Integration Planning Initiation
  • Pre-Integration Planning Activity Efficacy
  • Integration Planning Activity Resource Intensity
  • Integration Risk-Assessment Factor Importance
  • Integration Approach Assessments
  • Post-Deal Closure Integration Ownership
  • Time to Integration Stability By Organization Size
  • Performance Indicators for Integration Performance Measurement
  • M&A Activity Horizon